

Genetics, Maternal And Child Health (dinogmi), Dipartimento di Neuroscienze, Università di Genova, Genoa, Italy

\*Corresponding author.

doi: 10.1192/j.eurpsy.2021.262

**Introduction:** Experience of bullying may be a significant risk factor for non-suicidal self-injury (NSSI).

**Objectives:** This study had three aims: to systematically investigate the association between bullying and NSSI, to analyze the possible mechanisms underlying the two phenomena, and to evaluate any differences between bullying victimization and bullying perpetration with respect to NSSI.

**Methods:** A systematic search about the association between bullying victimization and perpetration and NSSI was conducted using specific databases (PubMed, Scopus, Science Direct). The following keywords were used in all database searches: “bullying” AND “NSSI” OR “peer victimization” and NSSI.

**Results:** The searches in PubMed, Scopus and Science Direct revealed a total of 88 articles about bullying or peer victimization and NSSI. However, only 29 met our inclusion criteria and were used for the present review. Overall, all studies examined victimization; 4 studies also evaluated the effects of perpetration and 1 included bully-victims. According to the main findings, both being a victim of bullying and perpetrating bullying may increase the risk of adverse psychological outcomes in terms of NSSI and suicidality in the short and the long run.

**Conclusions:** To the best of our knowledge, this is the first review to systematically evaluate the relation between bullying victimization/perpetration and NSSI. The main results support a positive association. Future research should evaluate the possible role of specific mediators/moderators of the association between experience of bullying and NSSI.

**Disclosure:** No significant relationships.

**Keywords:** Bullying perpetration; Bullying victimization; non-suicidal self-injury; adolescents

## Comorbidity/dual pathologies

### O044

#### Association between adult ADHD and generalised joint hypermobility, with and without systemic manifestations: A case-control study

M. Glans<sup>1\*</sup>, S. Bejerot<sup>1</sup>, M. Humble<sup>1</sup>, M. Elwin<sup>1</sup> and N. Thelin<sup>2</sup>

<sup>1</sup>Faculty Of Medicine And Health, Örebro University, Örebro, Sweden and <sup>2</sup>Division Of Psychiatry, Linköping University Hospital, Linköping, Sweden

\*Corresponding author.

doi: 10.1192/j.eurpsy.2021.263

**Introduction:** There is growing evidence that generalised joint hypermobility (GJH) is associated with several psychiatric conditions. There are no previous studies on adult ADHD.

**Objectives:** To evaluate, in a large Swedish sample, if generalised joint hypermobility and adult ADHD are associated.

**Methods:** 431 adults with ADHD and 417 controls were included. GJH was assessed by the Beighton Score, a physical examination, and the 5PQ, a self-report screening tool. Exploratively, reported musculoskeletal symptoms and abnormal skin manifestations suggestive of symptomatic GJH (e.g. Ehlers-Danlos syndrome), were assessed to differentiate this group from the general GJH group. Logistic regressions determined the influence of an ADHD diagnosis and known covariates (age, sex and ethnicity) on GJH and symptomatic GJH respectively.

**Results:** ADHD was associated to GJH, as defined by the Beighton Score and the 5PQ, with adjusted odds ratios of 4.65 (CI 95% 3.01-7.18,  $p < .005$ ) and 1.86 (CI 95% 1.39-2.48,  $p < .005$ ), respectively. Likewise, ADHD and symptomatic GJH were associated with adjusted odds ratios of 6.94 (CI 95% 4.05-11.89,  $p < .005$ ) and 2.66 (CI 95% 1.94-3.66,  $p < .005$ ).

**Conclusions:** GJH and adult ADHD are associated conditions. Symptomatic GJH, defined as additional symptoms of pain and/or skin manifestations, has a considerably stronger link to adult ADHD than unspecific GJH has. GJH may represent a marker of an underlying systemic disorder with physical manifestations in connective tissue as well as behavioural manifestations including hyperactivity, impulsiveness and inattentiveness. Future studies should investigate if this represents a novel subtype of ADHD and if symptomatic GJH affects the ADHD management.

**Disclosure:** No significant relationships.

**Keywords:** comorbidity; Hypermobility; ADHD; biomarkers

### O045

#### Substance-specific variability of ADHD symptoms in riga psychiatry and addiction medicine centre treatment-seeking substance use disorder outpatient population

M. Ennītis<sup>1\*</sup>, M. Laizāne<sup>1</sup>, N. Bezborodovs<sup>2</sup>, I. Landsmane<sup>3</sup> and S. Skaida<sup>4</sup>

<sup>1</sup>Faculty Of Residency, Riga Stradins University, Riga, Latvia;

<sup>2</sup>Department Of Psychiatry And Narcology, Riga Stradins University, Riga, Latvia; <sup>3</sup>Department Of Addiction Medicine, Riga Psychiatry and Narcology Centre, Riga, Latvia and <sup>4</sup>Department Of Psychiatry And Narcology, VSIA Riga Center of Psychiatry and Narcology, Riga, Latvia

\*Corresponding author.

doi: 10.1192/j.eurpsy.2021.264

**Introduction:** Studies show a link between attention deficit disorder (ADHD) and substance use disorders (SUD). Patients may abuse illicit drugs or alcohol as means of self-medicating e.g. stimulants for ADHD symptoms. Identifying ADHD symptoms in SUD patients could help improve treatment outcome and quality of life.

**Objectives:** To evaluate the prevalence of ADHD symptoms in Riga Psychiatry and Addiction Medicine Centre (RPNC) outpatients and study the link between ADHD symptoms and specific SUDs.

**Methods:** In a period of 30 days, all consentient clients of RPNC outpatient addiction clinic were surveyed for basic sociodemographic data and screened with Adult ADHD Self-report Scale (ASRSv1.1). Results were compared among patients with different types of addictions previously diagnosed using ICD-10 classification. Results were also compared to a control group.

**Results:** Out of 279 participants, 209 were treatment-seeking SUD patients, 70 controls. Mean age was 37.99, 77.8% were male. Among

SUD patients 45,2% had alcohol UD(F10), 52.9% opiate UD(F11), 35.1% stimulant UD(F14;f15), 20.2% sedative UD(F13). Patients who had stimulant addiction as one of their diagnosis and patients with multiple addictions were significantly more likely ( $p=0.023$  and  $p=0.012$  respectively) to screen positive for ASRSv1.1 among SUD patients population. All types of SUDs were significantly more likely to screen positive for ASRSv1.1 when compared to a control group.

**Conclusions:** There is a strong link between SUD and ADHD symptoms. Patients with stimulant or multiple SUDs are more likely to screen positive for ADHD symptoms than other SUD patients. It is important to identify ADHD symptoms in treatment-seeking SUD patients.

**Disclosure:** No significant relationships.

**Keywords:** ADHD; Substance Use Disorder; Adult Attention-Deficit / Hyperactivity Disorder; ASRS v.1.1

## O048

### Depression in multiple sclerosis: RS-fMRI research

A. Temniy<sup>1\*</sup>, K. Markin<sup>1</sup>, M. Poplyak<sup>2</sup>, A. Trufanov<sup>2</sup>, D. Tarumov<sup>1</sup> and I. Litvinenko<sup>2</sup>

<sup>1</sup>Psychiatry, S.M.Kirov Military Medical Academy, Saint-Petersburg, Russian Federation and <sup>2</sup>Neurology, S.M.Kirov Military Medical Academy, Saint-Petersburg, Russian Federation

\*Corresponding author.

doi: 10.1192/j.eurpsy.2021.265

**Introduction:** Multiple sclerosis (MS) is a demyelinating and neurodegenerative disorder of the CNS, which incapacitates people of working age. Due to progressive disability, the quality of life decreases, adding a number of other diseases to the main one. Several studies have reported high rates of depression in MS with a lifetime prevalence of approximately 50%.

**Objectives:** Therefore, we would like to pattern the functional activation of the brain of patients with different phenotypes of MS. This would objectify the patient's condition and the effectiveness of therapy for these diseases.

**Methods:** 68 patients with MS were examined: 40 with a relapsing-remitting type of course (RRMS) in remission and 28 with secondary - progressive MS (SPMS). Patients underwent MRI of the brain on a Siemens Tim Trio 3.0 T tomograph and processed the data using CONN 18b software. Clinical features were estimated by tests (BDI, HADS) results.

**Results:** 91% of all MS patients in research have signs of depression. We noted that decreased FC in RRMS patients has a whole-brain type, but it is only decreasing, not losing the connections between brain clusters. Decreased FC and losing the connections between large-scale brain networks and brain clusters. Due to tests, more severe depression was observed in SPMS patients.

**Conclusions:** Our findings suggest that patients with SPMS have depression, cause of decreasing in FC between the main clusters of the brain, and patients with SPMS have more severe depression, which, as we assume, neurodegeneration has turned into atrophy and losing all connections between clusters even in large-scale brain networks.

**Disclosure:** No significant relationships.

**Keywords:** Multiple sclerosis; Depression; rs-fMRI; comorbidity

## O049

### Evaluation of depression and anxiety control in greek patients with major depressive disorder with/without generalized anxiety disorder and cardiovascular disease-pronoi study

P. Papanastasiou<sup>1\*</sup>, P. Gourzis<sup>2</sup>, I. Nimatoudis<sup>3</sup> and A. Ginis<sup>1</sup>

<sup>1</sup>Medical Department, ELPEN Pharmaceutical Co. Inc., Attica, Greece;

<sup>2</sup>Department Of Psychiatry, School of Medicine, University of Patras, Patras, Greece and <sup>3</sup>Third Department Of Psychiatry, Aristotle University of Thessaloniki, Thessaloniki, Greece

\*Corresponding author.

doi: 10.1192/j.eurpsy.2021.266

**Introduction:** Patients with depression are likely to eventually develop Cardiovascular disease(CVD) and have a higher mortality rate than general population. In addition, anxiety disorders, especially Generalized Anxiety Disorder (GAD), may be associated with mortality and other adverse cardiac outcomes.

**Objectives:** Evaluation of depression and anxiety control in Greek patients with Major Depressive Disorder (MDD) with/without GAD and CVD, under 6 months of treatment with citalopram, and/or quetiapine, and/or pregabalin.

**Methods:** 565 patients with MDD with/without GAD, enrolled in this observational, study (NCT03317262). The subgroup of 133 (24%) patients had CVD. Severity of MDD and GAD symptoms was evaluated using the HAM-D and HAM-A Scores at baseline ( $V_1$ ) and after 6 months ( $V_3$ ) respectively.

**Results:** Mean HAM-D score in patients with CVD without GAD, at  $V_1$  and  $V_3$  was  $23.94 \pm 7.51$  and  $8.14 \pm 4.65$  respectively ( $p < 0.0001$ ). Similar results were observed in patients without CVD without GAD (HAM-D score  $26.67 \pm 8.79$  at  $V_1$  and  $7.44 \pm 4.40$  at  $V_3$ ). Mean HAM-A score in patients with CVD and GAD at  $V_1$  and  $V_3$  was  $25.64 \pm 6.38$  and  $8.98 \pm 3.93$ , respectively ( $p < 0.0001$ ). Same magnitude reduction in HAM-A score was observed in patients without CVD and GAD,  $26.27 \pm 8.16$  at  $V_1$  and  $9.28 \pm 6.48$  at  $V_3$  ( $p < 0.0001$ ). Patients' depression symptoms with/without CVD and GAD showed also a significant reduction between  $V_1$  and  $V_3$ .

**Conclusions:** MDD patients with CVD without GAD, had a marginally lower baseline HAM-D score versus patients with GAD. After 6 months of treatment with citalopram, and/or quetiapine, and/or pregabalin the improvement of depressive and anxiety symptoms was almost equal between MDD patients with/without GAD regardless of the presence of coexisting CVD.

**Disclosure:** Employee of ELPEN Pharmaceutical Co. Inc.

**Keywords:** Depression; Anxiety; comorbidities; cardiovascular

## O050

### Screening for hepatitis C in psychiatric population

F. Icole<sup>1\*</sup>, J.-P. Bronowicki<sup>2</sup>, C. Jeanneol<sup>3</sup>, P. Besancon<sup>3</sup> and F. Boulanger<sup>4</sup>

<sup>1</sup>Pôle De La Déodat, CHS Ravenel, Mirecourt, France; <sup>2</sup>Gastro-entérologie, CHRU Nancy, Vandoeuvre-lès-nancy, France; <sup>3</sup>Pôle Médico-technique, CHS Ravenel, Mirecourt, France and <sup>4</sup>Pôle Api, CHS Ravenel, Mirecourt, France

\*Corresponding author.

doi: 10.1192/j.eurpsy.2021.267